Home World News Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and... World News Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and Trametinib Over Targeted Therapy Alone for BRAF V600-mutated Metastatic Melanoma By Ogkologos - August 27, 2026 156 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMBI-I study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Thinking outside the box to tackle an aggressive children’s cancer September 8, 2021 ASCO Annual Meeting 2023: Improving Patients’ Lives Through Collaboration, Research, and... May 25, 2023 FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer January 17, 2025 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... October 19, 2020 Load more HOT NEWS Survivors of Childhood Cancer are at Excess Risk of Late Mortality... En gran cantidad de casos el exito o examen experto os... Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... Elections 2021: What the results mean for people with cancer
